A New Era in PAH: Reverse-remodeling Therapy - Advanced Clinical Cases

AMA/ANCC/ACPE Activity
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.
Pulmonary arterial hypertension (PAH) is a progressive and often fatal illness presenting with nonspecific symptoms of dyspnea, lower extremity edema, and exercise intolerance. Most of the available drugs and FDA‐approved therapies for treating pulmonary hypertension attempt to overcome the imbalance between vasoactive and vasodilator mediators and restore the endothelial cell function. New research has identified molecular targets that mediate vasodilation, anti‐inflammatory, and antifibrotic changes within the pulmonary vasculature.
This on-demand presentation will provide an updated overview of new therapeutic approaches under investigation for the treatment of PAH, as well as strategies to optimize outcomes for patients with PAH.
FACULTY
Marc Humbert, MD, PhD
Professor of Respiratory Medicine
Paris-Saclay University
Director, French Reference Centre for Pulmonary Hypertension
Hospital Bicêtre
Vallerie McLaughlin, MD
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
Professor of Internal Medicine
University of Michigan
Review the activity atbit.ly/3TKdWho and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.
This activity is provided in collaboration with Rush University Medical Center and Practice Point Communications
Supported by an independent educational grant from
Merck Sharp & Dohme LLC a subsidiary of Merck & Co., Inc.